Orbimed

Orbimed company information, Employees & Contact Information

Explore related pages

Related company profiles:

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Company Details

Employees
160
Founded
-
Address
601 Lexington Avenue,
Email
in****@****med.com
Industry
Investment Management
NAICS
Other Financial Investment Activities
Portfolio Management
All Other Financial Investment Activities
Trust, Fiduciary, and Custody Activities
Miscellaneous Financial Investment Activities
HQ
New York, NY
Looking for a particular Orbimed employee's phone or email?

Orbimed Questions

News

OrbiMed Raises $1.86 Billion for Healthcare Royalty & Credit Fund V - citybiz

OrbiMed Raises $1.86 Billion for Healthcare Royalty & Credit Fund V citybiz

Biovance Capital leads Series A Financing in Mondego Bio together with OrbiMed and Torrey Pines - PR Newswire

Biovance Capital leads Series A Financing in Mondego Bio together with OrbiMed and Torrey Pines PR Newswire

vVARDIS Secures $85M to Expand Globally - Dentistry Today

vVARDIS Secures $85M to Expand Globally Dentistry Today

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Yahoo Finance

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors Yahoo Finance

Swiss Dental Innovator vVARDIS Secures $35M Investment From OrbiMed - Dentistry Today

Swiss Dental Innovator vVARDIS Secures $35M Investment From OrbiMed Dentistry Today

Adjuvant Capital Joins $110 Million Series B For Curevo - citybiz

Adjuvant Capital Joins $110 Million Series B For Curevo citybiz

OrbiMed gets $1.86B for latest fund despite 'challenging' market - Fierce Biotech

OrbiMed gets $1.86B for latest fund despite 'challenging' market Fierce Biotech

Sam Isaly Remains at OrbiMed as Investors Consider Options - Institutional Investor

Sam Isaly Remains at OrbiMed as Investors Consider Options Institutional Investor

OrbiMed Raises $4.3 Billion Across Private Investment Funds - PR Newswire

OrbiMed Raises $4.3 Billion Across Private Investment Funds PR Newswire

OrbiMed Expands to Europe, Opens London Office - GlobeNewswire

OrbiMed Expands to Europe, Opens London Office GlobeNewswire

OrbiMed snags $1.9 billion for fifth healthcare fund amid 'challenging' market - FirstWord Pharma

OrbiMed snags $1.9 billion for fifth healthcare fund amid 'challenging' market FirstWord Pharma

Healthcare Investor OrbiMed Advisors Raises $4.3 Billion - The Wall Street Journal

Healthcare Investor OrbiMed Advisors Raises $4.3 Billion The Wall Street Journal

DIH Announces $1.5 million Private Placement Financing from OrbiMed - GlobeNewswire

DIH Announces $1.5 million Private Placement Financing from OrbiMed GlobeNewswire

Insmed Announces Strategic Financings Totaling $775 Million - PR Newswire

Insmed Announces Strategic Financings Totaling $775 Million PR Newswire

Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development - PR Newswire

Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development PR Newswire

OrbiMed: $1.86 Billion Raised For Healthcare Royalty & Credit Fund V - Pulse 2.0

OrbiMed: $1.86 Billion Raised For Healthcare Royalty & Credit Fund V Pulse 2.0

OrbiMed promotes Dr. Mona Ashiya to GP - Venture Capital Journal

OrbiMed promotes Dr. Mona Ashiya to GP Venture Capital Journal

PIC Therapeutics Closes $35 Million Series A Financing - citybiz

PIC Therapeutics Closes $35 Million Series A Financing citybiz

Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines - PR Newswire

Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines PR Newswire

xAI's raise, Nudge's noninvasive brain implant, and Stripe's buy - Axios

xAI's raise, Nudge's noninvasive brain implant, and Stripe's buy Axios

Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines - SynBioBeta

Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines SynBioBeta

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million - GlobeNewswire

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million GlobeNewswire

Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes - GlobeNewswire

Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes GlobeNewswire

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors - PR Newswire

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors PR Newswire

Legendary biotech financier Sam Isaly steps down following sexual harassment allegations - statnews.com

Legendary biotech financier Sam Isaly steps down following sexual harassment allegations statnews.com

2025 Biotech Fundraising Trends: A Two-Speed Capital Market - BioBuzz

2025 Biotech Fundraising Trends: A Two-Speed Capital Market BioBuzz

TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery - Business Wire

TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery Business Wire

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital - GlobeNewswire

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital GlobeNewswire

Their Hedge Fund’s Founder Was Accused of Sexual Harassment. Here’s What They Did Next. - Institutional Investor

Their Hedge Fund’s Founder Was Accused of Sexual Harassment. Here’s What They Did Next. Institutional Investor

Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say - statnews.com

Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say statnews.com

Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million - PR Newswire

Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million PR Newswire

Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines - PR Newswire

Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines PR Newswire

OrbiMed scores high returns from four-year-old India bet - VCCircle

OrbiMed scores high returns from four-year-old India bet VCCircle

Page 236 - Laotian Times

Page 236 Laotian Times

Orbimed invests in wheelchair maker Arcatron - Entrackr

Orbimed invests in wheelchair maker Arcatron Entrackr

Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team - PR Newswire

Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team PR Newswire

Top Orbimed Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant